EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Drug-Associated Vanishing Bile Duct Syndrome: Screening for Potential Pharmaceutical Triggers Using the WHO Pharmacovigilance Database

João Pereira Soares, Andreas E Kremer iD, Jérôme Bonzon iD

Life · 25.07.2026 · 16 (8) · 1232

DOI: 10.3390/life16081232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 25.07.2026. Verfasst von João Pereira Soares und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vanishing bile duct syndrome (VBDS) is a rare cholestatic liver disease often associated with drug-induced liver injury, yet systematic data on pharmaceutical triggers remain limited. Using WHO VigiBase, we applied Bayesian disproportionality analysis (IC0.25) to identify drug-event associations that may not be readily apparent in clinical trials or pre-marketing studies. Product labels approved by Swissmedic or the FDA, as well as LiverTox, were reviewed to determine whether VBDS was already acknowledged as an adverse event. Signal detection was deliberately restricted to reports naming a single suspect drug. Among these single-agent reports, 22 drugs demonstrated a positive IC0.25 signal, of which nevirapine, dapsone and azithromycin showed the strongest disproportionality signal. Only one of these agents (carbamazepine) explicitly labelled VBDS as an adverse event. These findings are based on spontaneous reporting data: disproportionality analysis is a hypothesis-generating signal-detection method that does not establish causality and requires further validation. This study expands the current understanding of drug-induced VBDS by reinforcing the associations with known drugs and generating pharmacovigilance signals for new potential VBDS triggers across several drug categories.

Schlagwörter

Stichwörter der Autor:innen

adverse drug eventdrug safetydrug-induced liver injuryhepatotoxicitypharmacovigilancevanishing bile duct syndrome

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.
  • Department of Gastroenterology and Hepatology, University Hospital Zurich, 8091 Zurich, Switzerland.

ORCID-Profile: Andreas E Kremer, Jérôme Bonzon

Zitieren

APA

Soares, J. P., Kremer, A. E., & Bonzon, J. (2026). Drug-Associated Vanishing Bile Duct Syndrome: Screening for Potential Pharmaceutical Triggers Using the WHO Pharmacovigilance Database. Life, 16(8), 1232. https://doi.org/10.3390/life16081232

Vancouver

Soares JP, Kremer AE, Bonzon J. Drug-Associated Vanishing Bile Duct Syndrome: Screening for Potential Pharmaceutical Triggers Using the WHO Pharmacovigilance Database. Life. 2026;16(8):1232. doi:10.3390/life16081232

BibTeX
@article{Soares2026,
  author = {Soares, João Pereira and Kremer, Andreas E and Bonzon, Jérôme},
  title = {Drug-Associated Vanishing Bile Duct Syndrome: Screening for Potential Pharmaceutical Triggers Using the WHO Pharmacovigilance Database},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {8},
  pages = {1232},
  doi = {10.3390/life16081232}
}
Kostenlos starten →